
Downloaded from: http://researchonline.lshtm.ac.uk/17522/

DOI: 10.1002/14651858.CD002045

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Hypertonic versus isotonic crystalloid for fluid resuscitation in critically ill patients (Unknown)

Bunn F, Roberts I, Tasker R, Akpa E

This is a reprint of a Cochrane unknown, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2002, Issue 1

http://www.thecochranelibrary.com

WILEY
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>2</td>
</tr>
<tr>
<td>RESULTS</td>
<td>2</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>2</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>3</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>3</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>5</td>
</tr>
</tbody>
</table>
Hypertonic versus isotonic crystalloid for fluid resuscitation in critically ill patients

F Bunn¹, I Roberts, R Tasker, E Akpa

¹Centre for Research in Primary and Community Care (CRIPACC), University of Hertfordshire, Hatfield, UK

Contact address:

Editorial group: Cochrane Injuries Group.

Citation: Bunn F, Roberts I, Tasker R, Akpa E. Hypertonic versus isotonic crystalloid for fluid resuscitation in critically ill patients. The Cochrane Database of Systematic Reviews, Issue . Art. No.: CD002045. DOI: 10.1002/14651858.CD002045.

Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Hypertonic solutions are considered to have a greater ability to expand blood volume and thus elevate blood pressure and can be administered as a small volume infusion over a short time period. On the other hand, the use of hypertonic solutions for volume replacement may also have important disadvantages.

Objectives
To determine whether hypertonic crystalloid decreases mortality in patients with hypovolaemia with and without head injuries.

Search strategy
We searched MEDLINE, EMBASE, The Cochrane Controlled Trials Register and the Specialised register of the Injuries Group. We checked reference lists of all articles identified and searched the National Research Register.

Selection criteria
Randomised trials comparing hypertonic to isotonic crystalloid in patients with trauma, burns or undergoing surgery.

Data collection and analysis
Two authors independently extracted the data and assessed the quality of the trials.

Main results
Seventeen trials were identified with a total of 869 participants. Data on death were obtained in twelve of the studies. Only one trial reported data on disability. The pooled RR for death in trauma patients was 0.84 (95% CI 0.61-1.16), in patients with burns 1.49 (95% CI 0.56-3.95), and in patients undergoing surgery 0.62 (95% CI 0.08-4.57). In the one trial that gave data on disability using the Glasgow Outcome Scale the relative risk was 0.99 (95% CI 0.06-15.93).

Reviewers’ conclusions
This review does not give us enough data to be able to say whether hypertonic crystalloid is better than isotonic crystalloid for the resuscitation of patients with trauma, burns, or those undergoing surgery. However, the confidence intervals are wide and do not exclude clinically significant differences. Further trials are needed comparing hypertonic to isotonic crystalloid. Trials need to be large enough to detect a clinically important difference.
Synopsis
To be added

BACKGROUND
Fluid resuscitation is a mainstay of the medical management of haemorrhagic hypovolaemia. However, there is continuing uncertainty about the most appropriate fluid (Krausz 1995). Isotonic crystalloid solutions are often used to replace blood loss until a blood transfusion can be administered, but the wish to administer large volumes (ATLS guidelines suggest two litres of isotonic crystalloid), particularly in the pre-hospital phase when there may be problems with venous access, has stimulated the development of alternative approaches. One such approach is the use of hypertonic saline. Hypertonic solutions are considered to have a greater ability to expand blood volume and thus elevate blood pressure and can be administered as a small volume infusion over a short time period (Krausz 1995). Infusion of hypertonic saline is believed to act by causing an osmotic shift of fluid from the intracellular and interstitial spaces to the extracellular compartment. The resulting auto-transfusion of fluid increases blood pressure and circulating volume. The use of hypertonic solutions has the potential to provide rapid volume resuscitation but with less interstitial oedema than with isotonic saline solutions (Shackford 1983).

It has also been suggested that hypertonic solutions may be the fluid of choice in hypovolaemic patients with head injuries (Walsh 1991, Peterson 2000, Khanna 2000). Cerebral perfusion pressure depends on both ICP and mean arterial blood pressure (CPP = mean arterial blood pressure - mean ICP). Patients in hypovolaemic shock who have head injuries may require rapid blood pressure elevation to maintain cerebral perfusion pressure but excessive fluid and salt administration may result in brain swelling with an increase in intracranial pressure. Hypertonic solutions however, are believed to reduce intracranial pressure by establishing an osmotic gradient across the blood brain barrier that draws water from the brain tissue into the vascular space (Fisher 1992). Hypertonic solutions therefore have the potential to rapidly restore blood pressure but without increasing intracranial pressure. Hypertonic solutions are also thought to be beneficial in preventing the 'water logging' effect when there is interstitial lung injury, for example as occurs both in elective surgery and in trauma.

On the other hand, the use of hypertonic solutions for volume replacement may also have important disadvantages. In situations where haemorrhage is on-going hypertonic solutions may result in continued bleeding from injured vessels. A potential problem in head injuries is that in patients with a disrupted blood brain barrier, excess sodium may leak into brain tissue drawing water with it, thus worsening cerebral oedema. At present there are no clinical ways to assess the integrity of the blood brain barrier. Furthermore, not only could the integrity of the blood brain barrier vary among patients with head injury, but it might also vary in different parts of the brain in a single patient. The possibility that hypertonic fluids may worsen outcome following head injury cannot therefore be dismissed (Krausz 1995, Shenkin 1976).

OBJECTIVES
To determine whether hypertonic crystalloid decreases mortality in patients with hypovolaemia with and without head injuries we conducted a systematic review of randomised controlled trials.

RESULTS
Death was reported either in the paper, or the information was obtained by contacting the researcher, in twelve of the studies. Data on death were not obtained for five trials (Gunn 1989, Jarvela 2001, McGough 1990, Younes 1988A, Younes 1988B). Only one trial (Vassar 1993A) reported data on disability.

Due to the clinical heterogeneity of the different patient groups it was felt to be inappropriate to pool them, therefore only the results for the subgroups are given. The pooled relative risk for death in trauma patients was 0.84 (95% CI 0.61-1.16), for patients with burns 1.49 (95% CI 0.56-3.95) and for patients undergoing surgery 0.62 (95% CI 0.08-4.57). Only the Vassar 1993a trial gave data on disability using the Glasgow outcome scale. In that trial one person in each group had a poor outcome. The relative risk was 0.99 (95% CI 0.06-15.93).

DISCUSSION
This review does not give us enough data to be able to say if hypertonic crystalloid is better than isotonic crystalloid for the resuscitation of patients with trauma or burns, or those undergoing...
surgery. However, the confidence intervals are wide and do not exclude clinically significant differences between hypertonic and isotonic crystalloid. A previous review (Alderson 1999) found there was a trend towards a favourable effect on mortality for colloids in hypertonic crystalloid compared to isotonic colloids, however, those results are compatible with the play of chance.

We chose not to pool the results of the burns, surgery and trauma patients as we felt these groups were too clinically heterogeneous. Bleeding and fluid management in patients undergoing elective surgery would tend to be more controlled and therefore different to that in trauma patients.

Most of the trials are small and quality was judged to be adequate in only five of them. There was variation in the type of participants, and length of follow up, and little standardisation in terms of fluid regimes. Also some of the trials were old. Although older trials will not necessarily be of poorer quality, it may be that treatment protocols have subsequently altered making these trials less relevant to current clinical practice. Indeed in the 1970s and 1980s there were few protocols on fluid resuscitation in the critically ill. Since the late 1980s there have been more clear guidelines and standardisation of fluid resuscitation regimes, although many areas of contention still exist.

Mortality was selected as the main outcome measure in this systematic review for several reasons. In the context of critical illness, death or survival is a clinically relevant outcome that is of immediate importance to patients, and data on death are reported in many of the studies. Furthermore, one might expect that mortality data would be less prone to measurement error or biased reporting than would data on pathophysiological outcomes. The use of a pathophysiological end point as a surrogate for an adverse outcome assumes a direct relationship between the two, an assumption that may sometimes be inappropriate. Finally, when trials collect data on a number of physiological end points, there is the potential for bias due to the selective publication of end points showing striking treatment effects.

Hypertonic solutions have been proposed as the fluid of choice in patients with head injuries (Walsh 1991), as they may maintain cerebral perfusion pressure without causing brain swelling with an increase in intracranial pressure. However, we found only one small trial (Simma 1998) among people with head injuries.

ACKNOWLEDGEMENTS
Thanks to Reinhard Wentz for help with the searches and to Phil Alderson for overseeing the editorial process.

REFERENCES

References to studies included in this review

Bortolani 1996 [published data only]

Caldwell 1979 [published data only]

Croft 1992 [published data only]

Cross 1989 [published data only]

Gunn 1989 [published data only]

Jarvela 2001 [published data only]
Jarvela K, Koskinen M, Kaukinen S, Koobi T. Effects of hypertonic saline (7.5%) on extracellular fluid volumes compared with normal saline (0.9%) and 6% hydroxyethyl starch after aortocoronary bypass graft surgery. Journal of Cardiothoracic and Vascular Anesthesia 2001;15(2):210-215.

Jelenko 1978 [published data only]

McGough 1990 [published data only]

Shackford 1983 [published data only]

Shackford 1987 [published data only]
Shackford SR, Fortlage DA, Peters RM, Hollingsworth-Fridlund, Sise MJ. Serum osmolar and electrolyte changes associated with large infusions of hypertonic sodium lactate for intravascular volume expansion of patients undergoing operations on the abdominal aorta.

**Simma 1998 (published data only)**


**Vassar 1990 (published data only)**


**Vassar 1993 A (published data only)**


**Vassar 1993 B (published data only)**


**Younes 1988A (published data only)**


**Younes 1988B (published data only)**


**Younes 1992 (published data only)**


**References to studies excluded from this review**

**Fisher 1992**


**Holcroft 1987**


**Shackford 1998**


**References to ongoing studies**

**Cooper**


**Cooper DJ**


**Additional references**

**Alderson 1999**


**Berlin 1997**


**Bickell 1994**


**Fisher 1992**


**Jennett 1975**


**Khanna 2000**


**Krausz 1995**


**Peterson 2000**

Schulz 1995

Shackford 1983

Shenkin 1976

Walsh 1991

* Indicates the major publication for the study.

**Sources of Support**

**External sources of support**
- NHS Research and Development UK

**Internal sources of support**
- No sources of support supplied